Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
levofloxacin inhalation solution
- Development stage
- Phase 3
- Lead developer
- Amgen
- Modality
- Small Molecules
- Administration
- Inhalation
01
Overview
Aeroquin is a proprietary aerosol formulation of levofloxacin, a fluoroquinolone antibiotic, developed for inhalation treatment of chronic Pseudomonas aeruginosa infections, particularly in patients with cystic fibrosis. It allows for direct delivery of high concentrations of the active drug to the site of infection in the lungs while minimizing systemic exposure.
- Brand names
- Quinsair
- Other names
- levofloxacin inhalation solution
02
Targets
DNA gyraseTopo IV (Bacterial Topoisomerase IV)
Beyond the preview
Go deeper on levofloxacin inhalation solution.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on levofloxacin inhalation solution.